AcetagastrodinCAS# 64291-41-4 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 64291-41-4 | SDF | Download SDF |
| PubChem ID | 163043 | Appearance | Powder |
| Formula | C21H26O11 | M.Wt | 454.43 |
| Type of Compound | Miscellaneous | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | [(2R,3R,4S,5R,6S)-3,4,5-triacetyloxy-6-[4-(hydroxymethyl)phenoxy]oxan-2-yl]methyl acetate | ||
| SMILES | CC(=O)OCC1C(C(C(C(O1)OC2=CC=C(C=C2)CO)OC(=O)C)OC(=O)C)OC(=O)C | ||
| Standard InChIKey | HGUDVDQXCUHOED-YMQHIKHWSA-N | ||
| Standard InChI | InChI=1S/C21H26O11/c1-11(23)27-10-17-18(28-12(2)24)19(29-13(3)25)20(30-14(4)26)21(32-17)31-16-7-5-15(9-22)6-8-16/h5-8,17-22H,9-10H2,1-4H3/t17-,18-,19+,20-,21-/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Acetagastrodin treatment may be an effective treatment to protect retinal neurons against such functional impairment during the early stages of diabetes. 2. Acetagastrodin has antispasmodic effect on vascular smooth muscle. |
Acetagastrodin Dilution Calculator
Acetagastrodin Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.2006 mL | 11.0028 mL | 22.0056 mL | 44.0112 mL | 55.014 mL |
| 5 mM | 0.4401 mL | 2.2006 mL | 4.4011 mL | 8.8022 mL | 11.0028 mL |
| 10 mM | 0.2201 mL | 1.1003 mL | 2.2006 mL | 4.4011 mL | 5.5014 mL |
| 50 mM | 0.044 mL | 0.2201 mL | 0.4401 mL | 0.8802 mL | 1.1003 mL |
| 100 mM | 0.022 mL | 0.11 mL | 0.2201 mL | 0.4401 mL | 0.5501 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Tetrahydropapaverine HCl
Catalog No.:BCC5321
CAS No.:6429-04-5
- Kielcorin
Catalog No.:BCN7637
CAS No.:64280-48-4
- Boc-N-Me-Tyr(Bzl)-OH
Catalog No.:BCC3356
CAS No.:64263-81-6
- Glutinol acetate
Catalog No.:BCN6675
CAS No.:6426-44-4
- Taraxasterol acetate
Catalog No.:BCN4184
CAS No.:6426-43-3
- L189
Catalog No.:BCC7707
CAS No.:64232-83-3
- Atracurium oxalate
Catalog No.:BCC8837
CAS No.:64228-78-0
- Thalirugidine
Catalog No.:BCN7706
CAS No.:64215-95-8
- CGP 12177 hydrochloride
Catalog No.:BCC6949
CAS No.:64208-32-8
- Antiarol
Catalog No.:BCN4185
CAS No.:642-71-7
- L-Quebrachitol
Catalog No.:BCN2727
CAS No.:642-38-6
- Alstonine
Catalog No.:BCN4606
CAS No.:642-18-2
- Galactopinitol A
Catalog No.:BCC8926
CAS No.:64290-91-1
- Dracorhodin
Catalog No.:BCC9226
CAS No.:643-56-1
- Malvidin chloride
Catalog No.:BCN3017
CAS No.:643-84-5
- N6-Benzoyl-5'-O-(4,4'-dimethoxytrityl)-2'-deoxyadenosine
Catalog No.:BCC9074
CAS No.:64325-78-6
- Alloalantolactone
Catalog No.:BCN8091
CAS No.:64340-41-6
- Precocene II
Catalog No.:BCN4605
CAS No.:644-06-4
- DL-2-Amino-n-octanoic acid
Catalog No.:BCC8949
CAS No.:644-90-6
- Mussaenoside
Catalog No.:BCN4186
CAS No.:64421-27-8
- Shanzhiside methylester
Catalog No.:BCN4187
CAS No.:64421-28-9
- Grifolin monomethyl ether
Catalog No.:BCN7568
CAS No.:64432-04-8
- Dulcoside A
Catalog No.:BCN3237
CAS No.:64432-06-0
- 10-Hydroxycamptothecin
Catalog No.:BCN1226
CAS No.:64439-81-2
Acetagastrodin effects on retinal oscillatory potentials in patients during the early stages of diabetes.[Pubmed:27650536]
Acta Diabetol. 2017 Jan;54(1):73-79.
AIMS: To investigate the protective effect of Acetagastrodin on visual electrophysiology in patients with early-stage diabetes. METHODS: A prospective, randomized, controlled, double-blind trial was conducted. Subjects who were randomly assigned to either the treatment group or the control group were orally administered Acetagastrodin or placebo, respectively, for 6 months. The quantity, mean amplitude and mean latency of oscillatory potentials (OPs) wavelets at baseline and 6 months were measured on electroretinogram (ERG), in all subjects. RESULTS: A total of 92 right eyes in 92 patients with type 2 diabetes, who were diagnosed for the first time, were enrolled. Each group consisted of 46 cases (46 eyes). There was no significant difference in baseline characteristic between treatment and control groups at baseline, but quantity in treatment group was more than that in control group at 6 months (P = 0.001). The mean amplitude of OPs was reduced in the control group 6 months later compared with treatment group (P = 0.001). As to mean latency of OPs, statistical difference was also detectable between the treatment group and control group 6 months later (P < 0.001). No statistical differences were found in hemoglobin between both groups at 6 months (P > 0.05). CONCLUSIONS: Electrophysiological changes would go on worsening even hemoglobin was under control during the initial stage of diabetes. Acetagastrodin treatment may be an effective treatment to protect retinal neurons against such functional impairment during the early stages of diabetes.
